drugset / Trial / NCT02597868
A Multicenter, Randomized Clinical Trail Evaluate Effectiveness and Security of Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen After the 1st-line Chemotherapy With Capecitabine Combine Regimen in Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer(Overstep)
Unknown
132 enrolled
Zhejiang Cancer Hospital
307 Hospital of PLA · collabFudan University · collabFujian Province Tumor Hospital · collabHangzhou Cancer Hospital · collabJiangsu Provincial People's Hospital · collabSir Run Run Shaw Hospital · collabThe Tumor Hospital of Jiangsu Province · collabZhejiang Chinese Medical University · collabZhejiang University · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
A multi-sites study about the efficacy of sequential monotherapy: Capecitabine vs. endocrine therapy, in metastatic breast cancer patients with HR-positive \& HER2-negative after capecitabine-base chemotherapy.
Timeline
- Start
- 2013-01
- Primary completion
- 2016-07
- Completion
- 2017-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Capecitabine | Small molecule | 1250 mg/m2 | Oral |